We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Kromek Group Plc | KMK | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 5.10 | 08:00:03 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 5.25 | 5.10 | 5.25 | 5.10 | 5.10 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 29/10/2024 10:14 by estienne Well here's a bit of itFull-year revenue up 12 per cent to £19.4mn Cash profit of £3.1mn well ahead of £1.2mn market estimate Underlying operating loss slashed from £6mn to £1.4mn Forecast positive cash flow in 2024/25 financial year New secured loan provides additional working capital Sedgefield-based Kromek (KMK:5.65p), a radiation detection technology group, materially outperformed house broker Cavendish’s full-year cash profit estimate even though revenue of £19.4mn was £1.6mn shy of expectations due to timing issues. Buoyed by the contribution from its higher-margin chemical, biological, radiological and nuclear (CBRN) detection business (revenue up 16 per cent to £7.1mn) and research and development activities (revenue up a fifth to £3mn), group gross margin of 55.2 per cent was seven percentage points higher than analysts had predicted and meant that gross profit increased 20 per cent to £10.7mn, well ahead of £10mn forecast. A focus on cost control contributed to the result, too. Total operating expenses decreased by £2.6mn to £12.6mn, or £1.3mn lower than Cavendish had predicted, hence a £2mn outperformance at the cash profit level and material reduction in operating loss. |
Posted at 28/10/2024 11:09 by earwacks Cash balance has always been a touchy subject with KmK unsurprisingly. Well they came up with half a million. Such a hard one to judge. They definitely have reasonably good growth after some sticky patches. However as fast as the growth accelerates so does dilution and debt. At some point would hope the balance would tip where they manage their first year without the need for more cash injection. As frustrating as this company has been, it might be just beginning to get there. Question is, does it need another year or will 2025 be the one for kmk. I suspect it will take at least 1 more year. Research tree are positive and even Stickopedia dont rate this the worst share ever now. I’m tempted again by the possible reward, but there are equally good investment cases with so many in the same boat.it just takes one hiccup. Its a struggle! |
Posted at 30/7/2024 11:18 by ark87 andrew97 - Literally what every investor here been hoping for since the IPO 11 years ago. share price was 49 back then btw!! With KMK history usually repeats itself. So right now they desperate for some hype job to get anonther placing off. What ever happened to those game changing covid detectors? |
Posted at 30/5/2024 12:36 by z1co Contract momentum builds at KromekRadiation detection technology company continues to win contracts from the medical imaging and nuclear markets. It has takeover potential too January 30, 2024 by Simon Thompson First half cash loss narrows from £2.7mn to £0.1mn Analysts push through material profit upgrades Sedgefield-based Kromek (KMK:5.8p), a radiation detection technology company, expects to report record revenue and return to cash profitability in the 12 months to 30 April 2024. The directors’ confidence is not misplaced if this week’s interim results are anything to go by. In the six-month period, Kromek won £8mn of orders including a contract worth $1.4mn (£1.1mn) from a new original equipment manufacturers (OEM) customer, an established player in the medical imaging sector in Asia. Kromek will supply its cadmium zinc telluride (CZT)-based detector modules for use in the company’s next-generation single-photon emission CT (SPECT)-based medical imaging scanners, and has won another four medical imaging orders from existing clients in recent weeks. |
Posted at 29/5/2024 20:21 by 33mick Well there is the hopefully soon to be announced development conclusion with Analogic who intend to incorporate CZT tech into a number of future products.Then the big one a Tier one global, everyone assumes Philips who are around about now after 12 months R&D work by Kmk on the cusp of releasing Thier first CZT based photon counting next gen scanner, both likely to be 7 multi Year supply contacts, then there's the CZT based ultra low dose breast imaging project due for some news, with US partners, so a bit of + news coming I think |
Posted at 29/5/2024 14:10 by z1co You can deramp this as much as you want to but reality is KMK is growing it's revenue and will eventually become profitable.It's a damn sight better than the pile of garbage RGB that you own. |
Posted at 29/5/2024 13:12 by jaknife Z1CO,I don't expect you to understand the simplicity of how the numbers work, or how hopelessly irrelevant the comment "EBITDA ahead of expectations" is. As noted above KMK will need to raise cash before September. So let us simply note for posterity that you said "buy" at 7.25p whilst I called you a dimwit and pointed out that a discounted placing was needed. Then we can revisit this in a few months and discuss it in more detail. It's a shame that we didn't do that when we discussed FAB, GDR or QED. And BTW, FWIW ROQ is a complete and utter total POS, it exists simply to part idiots from their cash to support the lifestyles of the insiders. JakNife |
Posted at 29/5/2024 12:19 by jaknife Kromek is a pile of sh-one-t. Year in, year out it pulls the wool over the eyes of amateur retail punters with some flim-flam BS only to raise funds in a discounted placing at the last minute.This time they claim that they'll be EBIDTA positive. Whoop whoop but what about actual profits? Cavendish forecast EBITDA of £1.2m for the full-year (to April 2024), which translates to a P&L loss of £5.3m. And normally KMK's cash losses exceed their P&L losses because they capitalise material expenses directly to the balance sheet (£4.8m worth last year). KMK reported cash of £3.7m at the interim stage (Oct 2023) and should burn cash of about £5m to £6m. Hence cash will run out before year end (Oct 2024) and, specifically cash will run out before they intend to publish the finals in September! Expect a discounted placing well before the finals are published. JakNife |
Posted at 30/4/2024 02:29 by ark87 Remeber that KMK started at 51p 12 years ago and back then Basu stated"Arnab Basu, CEO, commented: "We are delighted with our oversubscribed fundraising. After many years developing the business and our technology, Kromek is ready to begin harvesting value by seizing the opportunities to sell our technology and products into the medical imaging, security screening and nuclear detection markets." What went so wrong and how has Basu kept his job and such a nice wage? Wheres the accountability? |
Posted at 26/4/2024 03:08 by b00mb0y Yes. I agree. But a long way to go, yet, for my breakeven. Come on KMK! |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
